Vir Biotechnology
VIR

$10.70

0.38%

Market Cap: 1.46B

About: Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Employees: 587

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 11 analysts

0

News positive %

of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

13% more call options, than puts

Call options by funds: $3.04M | Put options by funds: $2.7M

8% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 66

3% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 30

2% more capital invested

Capital invested by funds: $887M [Q4 2023] → $904M (+$17.1M) [Q1 2024]

0.52% more ownership

Funds ownership: 65.52% [Q4 2023] → 66.04% (+0.52%) [Q1 2024]

0% more funds holding

Funds holding: 201 [Q4 2023] → 202 (+1) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 2 (+0) [Q1 2024]

See Fund Rankings

Research analyst outlook

11 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$9

16%

downside

Avg. target

$57

435%

upside

High target

$110

928%

upside

11 analyst ratings

7 positive

64%

4 neutral

36%

0 negative

0%

Morgan Stanley Michelle Gilson	40%upside $15	Equal-Weight Maintained	6 Jun 2024
HC Wainwright & Co. Patrick Trucchio	928%upside $110	Buy Reiterated	5 Jun 2024
Needham Joseph Stringer	78%upside $19	Buy Maintained	5 Jun 2024
HC Wainwright & Co. Patrick Trucchio	928%upside $110	Buy Reiterated	24 May 2024
HC Wainwright & Co. Patrick Trucchio	928%upside $110	Buy Reiterated	7 May 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about VIR published over the past 30 days

Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. Participants may ac.

Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024

Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis

VIR develops medicines for infectious and viral diseases using proprietary platforms for monoclonal antibodies and T cell-based Viral Vectors. Positive Phase 2 trial results for chronic hepatitis delta highlight the company's potential to address unmet medical needs. Strategic collaborations include the Bill & Melinda Gates Foundation, Alnylam Pharmaceuticals, and Gilead Sciences.

Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis

3 Undervalued Biotech Gems With 200%+ Analyst Price Targets

One of the critical components of the investing world is the proliferation and understanding of analyst predictions. That's because most retail investors prefer to research consumer information regarding stock picks through the calculations of those deemed more experienced in understanding financial fundamentals.

3 Undervalued Biotech Gems With 200%+ Analyst Price Targets

Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application and granted Fast Track designation for the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection. Tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, are currently being evaluated in the Company.

Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

Zacks Investment Research

Vir Biotechnology (VIR) Up on Positive Data From HDV Study

Vir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.

Vir Biotechnology (VIR) Up on Positive Data From HDV Study

Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment

SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #hepatitisd--New data from Vir Biotechnology reinforces the potential for a transformative treatment for hepatitis delta, the most severe form of viral hepatitis.

Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment

Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, at 11:00 a.m. PT / 2:00 p.m. ET at the Loews Miami Beach Hotel, Miami Beach, Florida. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir.

Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer (CMO), effective June 03, 2024. Dr. Eisner will be a part of the company's Executive Management Team and will report directly to Marianne De Backer, M.Sc., Ph.D., MBA, Vir's Chief Executive Officer. Dr. Eisner comes from Sonoma Biotherapeutics, Inc., where he most recently held the position of CMO. In.

Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer

Vir Biotechnology to Host 2024 Annual Meeting of Stockholders

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2024 Annual Meeting of Stockholders on Wednesday, May 29, 2024, at 9:00 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast. Vir Biotechnology's stockholders of record at the close of business on April 1, 2024, the record date for the Annual Meeting, can attend and vote at the Annual Meeting by accessing the meeting center at www.virtualshareh.

Vir Biotechnology to Host 2024 Annual Meeting of Stockholders

Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting new data from the Company's chronic hepatitis delta and chronic hepatitis B programs have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy from June 5-8. This includes an oral presentation on June 8, which was originally accepted as a late-breaker poster, that will hig.

Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024

See News Rankings